8/4/2019 60259273 Malignant Ovarian Tumour
1/42
MALIGNANT OVARIANMALIGNANT OVARIANTUMOURTUMOUR
By: Dr. Johara Al-MutawaBy: Dr. Johara Al-Mutawa
Assistant Professor &Assistant Professor &
ConsultantConsultant
8/4/2019 60259273 Malignant Ovarian Tumour
2/42
::
* It is common gynaecological tumour* It is common gynaecological tumour
continue to kill more women thancontinue to kill more women than
all other gynaecological cancerall other gynaecological cancer
* In England the incidents of ovarian* In England the incidents of ovarian
cancer 1.4 higher than cervical andcancer 1.4 higher than cervical andendometrial cancer but lower than breastendometrial cancer but lower than breast
cancer 7.1%cancer 7.1%
* Eventually 80 to 85% of women* Eventually 80 to 85% of women
with ovarian cancer diewith ovarian cancer die* Most ovarian cancer as epithelial in* Most ovarian cancer as epithelial in
origin and incidence increase riskorigin and incidence increase risk
with age.with age.
8/4/2019 60259273 Malignant Ovarian Tumour
3/42
Germ cell tumour rare and occur mainlyGerm cell tumour rare and occur mainly
in children and young women.in children and young women.
* Survival rater 5 years in 60% of stage I* Survival rater 5 years in 60% of stage I
disease ovarian malignancy.disease ovarian malignancy.
Histopathology and Classification ofHistopathology and Classification of
ovarian mass.ovarian mass.
* Ovarian mass Physiological* Ovarian mass Physiological
NeoplasticNeoplastic BenignBenign
MalignantMalignant
* WHO provide international classification* WHO provide international classification
that has been universally acceptedthat has been universally accepted
8/4/2019 60259273 Malignant Ovarian Tumour
4/42
Histological classification of ovarianHistological classification of ovarian
TumourTumour
Epithelial TumourEpithelial Tumour
* Serous Tumour* Serous Tumour* Mucinous Tumour* Mucinous Tumour
* Endometrial Tumour* Endometrial Tumour
* Clear Tumour* Clear Tumour
* Mixed Tumour* Mixed Tumour
* Undifferentiated and Unclassified* Undifferentiated and Unclassified
TumourTumour
8/4/2019 60259273 Malignant Ovarian Tumour
5/42
Sex-Cord Stromal tumoursSex-Cord Stromal tumours
* Granulosa stromal cell tumours* Granulosa stromal cell tumours* Sertoli stromal cell tumours* Sertoli stromal cell tumours
* Gynandroblastoma* Gynandroblastoma
* Sex cord tumour with annular tubules* Sex cord tumour with annular tubules
* Unclassified sex-cord tumoursSteroid cell* Unclassified sex-cord tumoursSteroid celltumourstumours
8/4/2019 60259273 Malignant Ovarian Tumour
6/42
Ovarian germ-cell tumoursOvarian germ-cell tumours
* Dysgerminoma* Dysgerminoma
* Teratoma (immature, mature and* Teratoma (immature, mature and
monodermal)monodermal)
* Yolk sac tumour (endodermal sinus* Yolk sac tumour (endodermal sinus
tumour)tumour)
* Embryonal carcinoma* Embryonal carcinoma
* Polyembryoma* Polyembryoma* Choriocarcinoma* Choriocarcinoma
* Mixed germ-cell tumour* Mixed germ-cell tumour
8/4/2019 60259273 Malignant Ovarian Tumour
7/42
Epithelial Tumour Arise from surface epithelium ofEpithelial Tumour Arise from surface epithelium of
ovary account from 60-65 % of ovarian tumour andovary account from 60-65 % of ovarian tumour and
approximately 90% are malignant.approximately 90% are malignant.
BenignBenign
border lineborder line
malignantmalignant
Sex cord stromal tumourSex cord stromal tumour
- Derived from sex cord & Stroma of ovary- Derived from sex cord & Stroma of ovary
- Account approximately 8% of all ovarian tumour- Account approximately 8% of all ovarian tumour
8/4/2019 60259273 Malignant Ovarian Tumour
8/42
Germ Cell Tumour =Germ Cell Tumour =
- Arise from germ cells- Arise from germ cells- Account from 30% of ovarian- Account from 30% of ovarian
tumour in the form of mature cysttumour in the form of mature cyst
tertoma (Dermoid Cysts) and 1 3tertoma (Dermoid Cysts) and 1 3
% of ovarian malignancy and% of ovarian malignancy and
represent 60% of ovarian cancer inrepresent 60% of ovarian cancer in
children and adolescents.children and adolescents.
8/4/2019 60259273 Malignant Ovarian Tumour
9/42
Epithelial ovarian tumour Epithelial ovarian tumour
*common bilateral*common bilateral
*Serous most common 40 *Serous most common 40
50%.50%.*Mucinous 10% large size*Mucinous 10% large size
associated withassociated withpseudomyxoma ovaripseudomyxoma ovari
8/4/2019 60259273 Malignant Ovarian Tumour
10/42
* Endometrial ovarian cancer: account* Endometrial ovarian cancer: account
for 20% of epithelial tumour. 10%for 20% of epithelial tumour. 10%
associated with endometrial cancer.associated with endometrial cancer.
* Brenner tumour very small proportion* Brenner tumour very small proportion
- 99% Benign- 99% Benign
* Clear Cell cancer Account from 5 10%* Clear Cell cancer Account from 5 10%
10%10%- Worse prognosis- Worse prognosis
* Mixed epethilium ovarian tumour* Mixed epethilium ovarian tumour
8/4/2019 60259273 Malignant Ovarian Tumour
11/42
Borderline ovarian tumour:Borderline ovarian tumour:
* Account approximately 15% of epithelial* Account approximately 15% of epithelialovarian cancer.ovarian cancer.
* They are low malignant potential.* They are low malignant potential.
* Affecting young women and may present* Affecting young women and may present
in pregnancyin pregnancy
* Microscopically they show malignant* Microscopically they show malignantfeatures but no stromal invasion.features but no stromal invasion.
* They have good prognosis.* They have good prognosis.
8/4/2019 60259273 Malignant Ovarian Tumour
12/42
Sex cord stromal tumours:Sex cord stromal tumours:
** They are composed of granuloza, thecaThey are composed of granuloza, thecaand serotoli cells.and serotoli cells.
* Granuloza cell tumour produce* Granuloza cell tumour produce
oestrogen and serotoli-stromal produceoestrogen and serotoli-stromal produceandrogen.androgen.
* Most of them are benign and most* Most of them are benign and most
clinically malignant are granuloza cell T.clinically malignant are granuloza cell T.
* Meig syyndrome - fibroma + ascites and* Meig syyndrome - fibroma + ascites and
8/4/2019 60259273 Malignant Ovarian Tumour
13/42
Germ Cell Tumour:Germ Cell Tumour:
* Account approximately 30% of ovarian* Account approximately 30% of ovariantumour.tumour.
* Commonest in the first two decade of* Commonest in the first two decade of
life.life.
* Sysgerminoma is the commonest* Sysgerminoma is the commonest
75% present in stage I disease75% present in stage I disease
10-15% Bilateral10-15% Bilateral
5-10% occur in female with abnormal5-10% occur in female with abnormal
gonadsgonads
8/4/2019 60259273 Malignant Ovarian Tumour
14/42
Teratomas: drived from 2 -3Teratomas: drived from 2 -3
embroyonic layersembroyonic layers
Mature (Dermoid Cysts) CommonestMature (Dermoid Cysts) Commonest
ovarian tumourovarian tumour
- Benign- Benign
- Unilateral (10-15% Bilateral)- Unilateral (10-15% Bilateral)
- Leading to torsion.- Leading to torsion.- Contain teeth and hair in the cyst.- Contain teeth and hair in the cyst.
- Malignant transformation 2%- Malignant transformation 2%
8/4/2019 60259273 Malignant Ovarian Tumour
15/42
Immature Teratoma:Immature Teratoma:
* 2* 2ndnd commonest germ cell malignancy.commonest germ cell malignancy.
* Account for 20% ovarian cancer in* Account for 20% ovarian cancer infemale under 20 years of age.female under 20 years of age.
* Unilateral* Unilateral
* classified according to differentiation* classified according to differentiation
and quantity of immature tissue.and quantity of immature tissue.
8/4/2019 60259273 Malignant Ovarian Tumour
16/42
Embryonic Markers:Embryonic Markers:
* Yolk sac tumour AFP - (rare tumor)* Yolk sac tumour AFP - (rare tumor)
* Ovarian choriocarcinoma secret BHCG* Ovarian choriocarcinoma secret BHCG(rare tumour)(rare tumour)
* Normal level does not exclude diagnosis.* Normal level does not exclude diagnosis.
* Teratoma & dysgemenoma does not* Teratoma & dysgemenoma does not
secret this tumor marker.secret this tumor marker.
8/4/2019 60259273 Malignant Ovarian Tumour
17/42
Secondary ovarian malignancy:Secondary ovarian malignancy:
* Account up to 10%.* Account up to 10%.
* Metastases form Colon* Metastases form Colon
StomachStomach
BreastBreast
Female genitalFemale genitaltracttract
8/4/2019 60259273 Malignant Ovarian Tumour
18/42
Krukenberg Tumour: BilateralKrukenberg Tumour: Bilateral
enlarged ovariesenlarged ovaries
* Ovarian metastatic tumour from* Ovarian metastatic tumour from
gastric or colon cancer.gastric or colon cancer.
* Microscopic assessment signet* Microscopic assessment signet
ring cells.ring cells.
* CEA marker increase* CEA marker increase
8/4/2019 60259273 Malignant Ovarian Tumour
19/42
Eitology:Eitology:
* Environmental Factors:* Environmental Factors:
- Unknown- Unknown
- High fat diet- High fat diet
- Perineal dusting with talcum powder- Perineal dusting with talcum powder- Risk of caffeine intake and radiation- Risk of caffeine intake and radiation
unclean.unclean.
- Role of certain viral infection (Mumps,- Role of certain viral infection (Mumps,
rubella, influenza) inconclusive results.rubella, influenza) inconclusive results.
8/4/2019 60259273 Malignant Ovarian Tumour
20/42
Reproductive and Hormonal factors:Reproductive and Hormonal factors:
* Contraceptive pill* Contraceptive pill* Pregnancy* Pregnancy
* Breast feeding* Breast feeding
* Tubal ligation and Hysterectomy* Tubal ligation and Hysterectomy
- early menarche- early menarche
- late menopause- late menopause
- nulliparity- nulliparity
8/4/2019 60259273 Malignant Ovarian Tumour
21/42
This suggest continous ovulation isThis suggest continous ovulation is
important factor.important factor.
* Using of ovulatory stimulants and* Using of ovulatory stimulants and
subsequent development of epithelialsubsequent development of epithelial
ovarian cancer is currently lacking.ovarian cancer is currently lacking.
* Heriditary factors not more than 10% of* Heriditary factors not more than 10% of
all ovarian cancer.all ovarian cancer.
* BRCAI responsible for 5% of ovarian* BRCAI responsible for 5% of ovarian
cancer in young women < 40 years.cancer in young women < 40 years.
8/4/2019 60259273 Malignant Ovarian Tumour
22/42
Screening of ovarian cancer:Screening of ovarian cancer:
* No role of ovarian screening in* No role of ovarian screening inasymptomatic population.asymptomatic population.
* Women at risk of developing ovarian* Women at risk of developing ovarian
cancer based on family history 10%cancer based on family history 10%offered screening.offered screening.
* Women risk vague pelvic abdominal* Women risk vague pelvic abdominal
symptoms warrant complete history andsymptoms warrant complete history andexamination including vaginal and rectalexamination including vaginal and rectal
examination.examination.
8/4/2019 60259273 Malignant Ovarian Tumour
23/42
Risk of Malignancy index (RMI)Risk of Malignancy index (RMI)
Serum Ca 12.5Serum Ca 12.5
USS Score (0-3) calculated by:USS Score (0-3) calculated by:
multilocular cystsmultilocular cysts
Solid areaSolid area
Bilateral lessionBilateral lession
MetastasisMetastasis
AscitesAscites
Menopausal status 1 for premenopausalMenopausal status 1 for premenopausal
3 for post menopausal3 for post menopausal
8/4/2019 60259273 Malignant Ovarian Tumour
24/42
This RMI to identify cases for referral toThis RMI to identify cases for referral to
Gynaecology OncologistGynaecology Oncologist
Symptoms:Symptoms:
* Early stage Pressure symptom* Early stage Pressure symptom
* Late stage metastatic effect to bowel* Late stage metastatic effect to bowel
mesentery and ascites.mesentery and ascites.- Vaginal bleeding less- Vaginal bleeding less
common.common.
8/4/2019 60259273 Malignant Ovarian Tumour
25/42
Clinical Signs:Clinical Signs:
* Supraclavicular, axillary, inguinal lymph* Supraclavicular, axillary, inguinal lymph
nodes.nodes.
* Breast examination* Breast examination* Chest examination pleural effusion* Chest examination pleural effusion
* Abdominal examination liver size* Abdominal examination liver size
* Pelvic & rectal examination Irregular* Pelvic & rectal examination Irregular
solid mass suggestive of malignancy.solid mass suggestive of malignancy.
8/4/2019 60259273 Malignant Ovarian Tumour
26/42
INVESTIGATIONSINVESTIGATIONS- For blood count- For blood count
- Urea and electrolyte- Urea and electrolyte- Liver function test- Liver function test
- Tumor marker- Tumor marker
- Ca 125- Ca 125
AFP & B-HCGAFP & B-HCG
- CEA- CEA- U/S for pelvis, kidney and liver- U/S for pelvis, kidney and liver
- MIR- MIR- CT Scan- CT Scan
- Endometrial biopsy- Endometrial biopsy
- Endoscopy- Endoscopy
8/4/2019 60259273 Malignant Ovarian Tumour
27/42
Staging of primary ovarian cancer:Staging of primary ovarian cancer:
Stage Description 5 yearStage Description 5 yearsurvivalsurvival
(%)(%)
I Confined to one/both ovariesI Confined to one/both ovaries
Ia Limited to a single ovary, no ascites; 89.9Ia Limited to a single ovary, no ascites; 89.9
capsule intact with no surface tumourcapsule intact with no surface tumourIb Limited to both ovaries, no ascites; 84.7Ib Limited to both ovaries, no ascites; 84.7
capsule intact with no surface tumourcapsule intact with no surface tumour
Ic One or both ovaries have ruptured 80Ic One or both ovaries have ruptured 80
capsule or surface tumour, malignantcapsule or surface tumour, malignant
ascites or positive peritoneal washingsascites or positive peritoneal washings
II Extension to pelvic structuresII Extension to pelvic structuresIIa Extension to uterus or fallopian tubes 69.9IIa Extension to uterus or fallopian tubes 69.9
IIb Extension to other pelvic tissues 63.7IIb Extension to other pelvic tissues 63.7
IIc As for IIA or IIB but one or both ovaries 66.5IIc As for IIA or IIB but one or both ovaries 66.5
have ruptured capsule or surface tumour;have ruptured capsule or surface tumour;
malignant ascites or positivemalignant ascites or positive
peritoneal washingsperitoneal washings
8/4/2019 60259273 Malignant Ovarian Tumour
28/42
III As for stage I/II but also with peritonealIII As for stage I/II but also with peritoneal
Implants outside pelvis or with positiveImplants outside pelvis or with positive
retroperitoneal lymph nodesretroperitoneal lymph nodes
IIIa Histologically confirmed microscopicIIIa Histologically confirmed microscopic58.558.5
seeding of abdominal peritoneal surfacesseeding of abdominal peritoneal surfaces
and negative retroperitoneal lymph nodesand negative retroperitoneal lymph nodes
IIIb Histologically confirmed implants ofIIIb Histologically confirmed implants of
39.939.9 abdominal peritoneal surfaces
8/4/2019 60259273 Malignant Ovarian Tumour
29/42
Metastatic ovarian spread:Metastatic ovarian spread:
* Direct tubes uterus - bladder* Direct tubes uterus - bladder* Trascoelmic along peritoneal surface.* Trascoelmic along peritoneal surface.
* Lymphatic spread pelvic and para* Lymphatic spread pelvic and para
aortic lymph nodes.aortic lymph nodes.
* Haematogenous spread - liver* Haematogenous spread - liver- lung- lung
8/4/2019 60259273 Malignant Ovarian Tumour
30/42
Technique for Surgical Staging:Technique for Surgical Staging:
* Midline incision adequate access for* Midline incision adequate access for
surgical staging and full inspections.surgical staging and full inspections.
1. Sending ascites or peritoneal washing1. Sending ascites or peritoneal washing2. Performing total hystrectomy and2. Performing total hystrectomy and
bilateral salpingo ophorectomy.bilateral salpingo ophorectomy.
3. Omentectomy3. Omentectomy
4. Peritoneal biopsy all suspicious area.4. Peritoneal biopsy all suspicious area.5. Diaphragmatic biopsy or scraping.5. Diaphragmatic biopsy or scraping.
6. Sampling of pelvic and a paraaortic6. Sampling of pelvic and a paraaortic
lymph nodes.lymph nodes.
S i l M t f O i
8/4/2019 60259273 Malignant Ovarian Tumour
31/42
Surgical Management of OvarianSurgical Management of Ovarian
Cancer:Cancer:
* Primary surgery in early epithelial* Primary surgery in early epithelial
ovarian cancer.ovarian cancer.
In young patient fertility is important:In young patient fertility is important:* Laparotomy is gold, standard for* Laparotomy is gold, standard for
diagnosis and stagingdiagnosis and staging
* Frozen section is useful.* Frozen section is useful.
* Delaying procedure until histopathology* Delaying procedure until histopathology
is available regardin further surgicalis available regardin further surgical
management to be made in consultationmanagement to be made in consultation
with patient and cancer team.with patient and cancer team.
8/4/2019 60259273 Malignant Ovarian Tumour
32/42
Primary surgery in advanced epitheliumPrimary surgery in advanced epithelium
ovarian cancer.ovarian cancer.
* Primary cytoreductive surgery followed* Primary cytoreductive surgery followed
by chemotherapy is current goldby chemotherapy is current goldstandard.standard.
* Cytoreductive surgery remove all* Cytoreductive surgery remove all
primary cancer and if possibleprimary cancer and if possiblemetastatic disease to tumor load tometastatic disease to tumor load to
achieve optimal status.achieve optimal status.
Ch thCh th
8/4/2019 60259273 Malignant Ovarian Tumour
33/42
Chemotherapy:Chemotherapy:
** Additional therapy in early stage diseaseAdditional therapy in early stage diseasewith high risk factor.with high risk factor.
* Standard adjuvant depending involve IV* Standard adjuvant depending involve IV
chemotherapy single agent active inchemotherapy single agent active in
epithelial ovarian cancer.epithelial ovarian cancer.
Include: Alkalizing agent (cyclophosophomide)Include: Alkalizing agent (cyclophosophomide)
- platinuim compound (cisplatin)- platinuim compound (cisplatin)
- taxanes (paclitaxel)- taxanes (paclitaxel)- paclitaxel and platinum became new standard- paclitaxel and platinum became new standard
of care in advanced ovarian cancer.of care in advanced ovarian cancer.
- pallative surgery bowel obstruction involve - pallative surgery bowel obstruction involve
bowel resection and intestinal bypass.bowel resection and intestinal bypass.
GG ll t
8/4/2019 60259273 Malignant Ovarian Tumour
34/42
Germ cell tumour:Germ cell tumour:
* Adequate surgical staging.* Adequate surgical staging.* Cytoreduction and adjuvant* Cytoreduction and adjuvant
chemotherapy is the standard therapy.chemotherapy is the standard therapy.
* Usually occur in young patient so* Usually occur in young patient so
conservative of contralateral ovary andconservative of contralateral ovary anduterus is appropriate.uterus is appropriate.
* In dysgeminoma and Immature tertoma* In dysgeminoma and Immature tertoma
stage I ovarian cancer further therapy.stage I ovarian cancer further therapy.
From all after patient 2-3 cycles ofFrom all after patient 2-3 cycles ofcombination therapy.combination therapy.
** Tumor marker useful in monitoringTumor marker useful in monitoring
disease and planning management.disease and planning management.
8/4/2019 60259273 Malignant Ovarian Tumour
35/42
Sex cord stromal tumour:Sex cord stromal tumour:
Surgery is the gold standard butSurgery is the gold standard but
early stage can be managed byearly stage can be managed byunilateral oophorectomy andunilateral oophorectomy and
endometrial biopsy when fertility isendometrial biopsy when fertility isimportant.important.
8/4/2019 60259273 Malignant Ovarian Tumour
36/42
Treatment of ovarian CancerTreatment of ovarian Cancer
The principle of TreatmentThe principle of Treatment
1. Surgical staging Laparotomy to classify the1. Surgical staging Laparotomy to classify the
growth to its extent of spread.growth to its extent of spread.
2. Surgical removal of as much malignant2. Surgical removal of as much malignant
tissue as possible( surgical debulking; cyto-tissue as possible( surgical debulking; cyto-reductive treatment), may involve partialreductive treatment), may involve partial
resection of bladder and bowel.resection of bladder and bowel.
3. Follow up with intensive chemotherapy using3. Follow up with intensive chemotherapy using
various combination of drugs Toxanes withvarious combination of drugs Toxanes withplatinium are first choice of treatment.platinium are first choice of treatment.
4. Second look laparatomy or laparoscopy to4. Second look laparatomy or laparoscopy to
determine effectiveness of chemotherapydetermine effectiveness of chemotherapy
only performed for clinical trails.only performed for clinical trails.
8/4/2019 60259273 Malignant Ovarian Tumour
37/42
- Cooperation with general surgeon and- Cooperation with general surgeon and
experience in field of chemotherapy andexperience in field of chemotherapy and
radiotherapy.radiotherapy.
- Treatment by radiotherapy only for pallation.- Treatment by radiotherapy only for pallation.- CA 125 is usually raised in advanced ovarian- CA 125 is usually raised in advanced ovarian
cancer and used to assess response tocancer and used to assess response to
chemotherapy.chemotherapy.
Chemotherapy:Chemotherapy:
- Act by inhibiting cell deviation- Act by inhibiting cell deviation
* Alkalyting agent preventing replication of DNA* Alkalyting agent preventing replication of DNA
- cyclophosphoamide- cyclophosphoamide
- Chloraambucil- Chloraambucil
*A ti it ti tibi ti P t DNA*Antimitotic antibiotic Prevent DNA
8/4/2019 60259273 Malignant Ovarian Tumour
38/42
*Antimitotic antibiotic Prevent DNA*Antimitotic antibiotic Prevent DNA
protein synthesis actinomycin Dprotein synthesis actinomycin D
Antimetabolites: Preventing the synthesisAntimetabolites: Preventing the synthesis
of nucleoproteinof nucleoprotein
Methotrexate:Methotrexate:
Other Non Alkylating agentOther Non Alkylating agent
* Cisplatin* Cisplatin
-Carboplatin-Carboplatin
* Taxanes Paclitaxel* Taxanes Paclitaxel
8/4/2019 60259273 Malignant Ovarian Tumour
39/42
Toxicity:Toxicity:
- Bone marrow depression- Bone marrow depression- gastrointestinal- gastrointestinal
- neurotoxic- neurotoxic
- nephrotoxic- nephrotoxic
- alopecia- alopecia
- candiatoxic- candiatoxic
- liver failure- liver failure
- regular check up for marrow and liver- regular check up for marrow and liverfunctionfunction
8/4/2019 60259273 Malignant Ovarian Tumour
40/42
Prognosis for epithelial ovarian cancerPrognosis for epithelial ovarian cancer
Stage 5 years survivalStage 5 years survival
I 60 70%I 60 70%
II 40 - 50%II 40 - 50%
III 5 - 10%III 5 - 10%
IV nilIV nil
8/4/2019 60259273 Malignant Ovarian Tumour
41/42
Borderline epithelial Tumour - hasBorderline epithelial Tumour - hasexcellent prognosisexcellent prognosis
-- 5 years 90 95%5 years 90 95%
- 15 years survival 70-85%- For serous- 15 years survival 70-85%- For seroustumourtumour
- 5-10% for mucinous- 5-10% for mucinous
- Chemotherapy is effective in the in frequent- Chemotherapy is effective in the in frequent
germ cell tumourgerm cell tumour
8/4/2019 60259273 Malignant Ovarian Tumour
42/42
Thank you andThank you and
Good Luck!Good Luck!